Achieve life sciences reaches agreement with the fda on long-term cytisinicline exposure data requirements for nda submission

Open-label exposure trial expected to initiate in q2'24 with nda filing anticipated in 1h 2025 open-label exposure trial expected to initiate in q2'24 with nda filing anticipated in 1h 2025

ACHV Ratings Summary

ACHV Quant Ranking